{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:32:27Z","timestamp":1792186347554,"version":"4.4.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","award":["CS-2013-13-032"],"award-info":[{"award-number":["CS-2013-13-032"]}],"id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leeds Teaching Hospitals NHS Trust"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine whether SLE patients with inflammatory joint symptoms and US synovitis\/tenosyovitis achieve better clinical responses to glucocorticoids compared with patients with normal scans. Secondary objectives included identification of clinical features predicting US synovitis\/tenosynovitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a longitudinal multicentre study, SLE patients with physician-diagnosed inflammatory joint pain received intramuscular methylprednisolone 120\u2009mg once. Clinical assessments, patient-reported outcomes and bilateral hand\/wrist USs were collected at 0, 2 and 6 weeks. The primary outcome (determined via internal pilot) was the early morning stiffness visual analogue scale (EMS-VAS) at 2\u2009weeks, adjusted for baseline, comparing patients with positive (greyscale \u22652 and\/or power Doppler \u22651) and negative US. Post hoc analyses excluded FM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 133 patients, 78 had a positive US. Only 53 (68%) of these had one or more swollen joint. Of 66 patients with one or more swollen joint, 20% had a negative US. A positive US was associated with joint swelling, symmetrical small joint distribution and serology. The primary endpoint was not met: in the full analysis set (N\u2009=\u2009133) there was no difference in baseline-adjusted EMS-VAS at week 2 [\u22127.7\u2009mm (95% CI \u221219.0, 3.5); P\u2009=\u20090.178]. After excluding 32 patients with FM, response was significantly better in patients with a positive US at baseline [baseline-adjusted EMS-VAS at 2\u2009weeks \u221212.1\u2009mm (95% CI \u221222.2, \u22120.1); P\u2009=\u20090.049]. This difference was greater when adjusted for treatment [\u221212.8\u2009mm (95% CI \u221222, \u22123); P\u2009=\u20090.007]. BILAG and SLEDAI responses were higher in US-positive patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In SLE patients without FM, those with a positive US had a better clinical response to therapy. Imaging-detected synovitis\/tenosynovitis may be considered to decide on therapy and enrich clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab288","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T19:14:01Z","timestamp":1617218041000},"page":"5194-5204","source":"Crossref","is-referenced-by-count":31,"title":["Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study"],"prefix":"10.1093","volume":"60","author":[{"given":"Khaled","family":"Mahmoud","sequence":"first","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S","family":"Zayat","sequence":"additional","affiliation":[{"name":"Bradford Teaching Hospitals NHS Foundation Trust, Bradford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Yuzaiful Md","family":"Yusof","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust"},{"name":"NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Dutton","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust"},{"name":"NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee Suan","family":"Teh","sequence":"additional","affiliation":[{"name":"Royal Blackburn Teaching Hospital, Blackburn and University of Central Lancashire, Preston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee-Seng","family":"Yee","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Doncaster and Bassetlaw Teaching Hospitals, NHS Foundation Trust, Doncaster"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Cruz","sequence":"additional","affiliation":[{"name":"Guys and St Thomas Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Ng","sequence":"additional","affiliation":[{"name":"Guys and St Thomas Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-2455","authenticated-orcid":false,"given":"David","family":"Isenberg","sequence":"additional","affiliation":[{"name":"University College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8911-4113","authenticated-orcid":false,"given":"Coziana","family":"Ciurtin","sequence":"additional","affiliation":[{"name":"Centre for Adolescent Rheumatology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G","family":"Conaghan","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8482","authenticated-orcid":false,"given":"Paul","family":"Emery","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Edwards","sequence":"additional","affiliation":[{"name":"NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-4755","authenticated-orcid":false,"given":"Elizabeth M A","family":"Hensor","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-4755","authenticated-orcid":false,"given":"Edward M","family":"Vital","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"2021110402575348700_keab288-B1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/BOR.0000000000000421","article-title":"Musculoskeletal manifestations of systemic lupus erythmatosus","volume":"29","author":"Mahmoud","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"2021110402575348700_keab288-B2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/03009742.2012.677857","article-title":"An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life","volume":"41","author":"Pettersson","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"2021110402575348700_keab288-B3","first-page":"485","article-title":"The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review","volume":"55","author":"Zayat","year":"2016","journal-title":"Rheumatology"},{"key":"2021110402575348700_keab288-B4","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2021110402575348700_keab288-B5","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2021110402575348700_keab288-B6","first-page":"336","article-title":"Summarizing disease features over time: II. Variability measures of SLEDAI-2K","volume":"34","author":"Ibanez","year":"2007","journal-title":"J Rheumatol"},{"key":"2021110402575348700_keab288-B7","volume-title":"Belimumab for treating active autoantibody-positive systemic lupus erythematosus","year":"2016"},{"key":"2021110402575348700_keab288-B8","first-page":"485","article-title":"The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review","volume":"55","author":"Zayat","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2021110402575348700_keab288-B9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/rheumatology\/key277","article-title":"Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus","volume":"58","author":"Zayat","year":"2019","journal-title":"Rheumatology"},{"key":"2021110402575348700_keab288-B10","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021110402575348700_keab288-B11","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.22881","article-title":"Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus","volume":"57","author":"McElhone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021110402575348700_keab288-B12","doi-asserted-by":"crossref","first-page":"e000428","DOI":"10.1136\/rmdopen-2016-000428","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce \u2013 part 1: definition and development of a standardised, consensus-based scoring system","volume":"3","author":"D\u2019Agostino","year":"2017","journal-title":"RMD Open"},{"key":"2021110402575348700_keab288-B13","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/annrheumdis-2012-202092","article-title":"Reliability of a consensus-based ultrasound score for tenosynovitis in rheumatoid arthritis","volume":"72","author":"Naredo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021110402575348700_keab288-B14","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/rheumatology\/key422","article-title":"Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus","volume":"58","author":"Mahmoud","year":"2019","journal-title":"Rheumatology"},{"key":"2021110402575348700_keab288-B15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2474-15-28","article-title":"Measurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic review","volume":"15","author":"van Tuyl","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"2021110402575348700_keab288-B16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0895-4356(97)00051-6","article-title":"Measurement of morning stiffness in rheumatoid arthritis clinical trials","volume":"50","author":"Vliet Vlieland","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"2021110402575348700_keab288-B17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00296-019-04506-2","article-title":"Fibromyalgia interferes with disease activity and biological therapy response in inflammatory rheumatic diseases","volume":"40","author":"Benlidayi","year":"2020","journal-title":"Rheumatol Int"},{"key":"2021110402575348700_keab288-B18","first-page":"980","article-title":"A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis","volume":"12","author":"Clark","year":"1985","journal-title":"J Rheumatol"},{"key":"2021110402575348700_keab288-B19","first-page":"S40","article-title":"Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus","volume":"34","author":"Torrente-Segarra","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2021110402575348700_keab288-B20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/rheumatology\/ket376","article-title":"Ultrasound evaluation of hand, wrist and foot joint synovitis in systemic lupus erythematosus","volume":"53","author":"Iagnocco","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2021110402575348700_keab288-B21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jbspin.2018.01.013","article-title":"Ultrasonography and detection of subclinical joints and tendons involvements in systemic lupus erythematosus (SLE) patients: a cross-sectional multicenter study","volume":"85","author":"Salliot","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2021110402575348700_keab288-B22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jclinepi.2013.11.013","article-title":"Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0","volume":"67","author":"Boers","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2021110402575348700_keab288-B23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41584-019-0235-5","article-title":"New therapies for systemic lupus erythematosus \u2013 past imperfect, future tense","volume":"15","author":"Murphy","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2021110402575348700_keab288-B24","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021110402575348700_keab288-B25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2021110402575348700_keab288-B26","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021110402575348700_keab288-B27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/acr.22921","article-title":"Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years","volume":"69","author":"Aguiar","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2021110402575348700_keab288-B28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021110402575348700_keab288-B29","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0961203313509295","article-title":"Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis","volume":"22","author":"Duxbury","year":"2013","journal-title":"Lupus"},{"key":"2021110402575348700_keab288-B30","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021110402575348700_keab288-B31","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2021110402575348700_keab288-B32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2021110402575348700_keab288-B33","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/rheumatology\/keu215","article-title":"A study of erosive phenotypes in lupus arthritis using magnetic resonance imaging and anti-citrullinated protein antibody, anti-RA33 and RF autoantibody status","volume":"53","author":"Ball","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2021110402575348700_keab288-B34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00296-019-04506-2","article-title":"Fibromyalgia interferes with disease activity and biological therapy response in inflammatory rheumatic diseases","volume":"40","author":"Coskun Benlidayi","year":"2020","journal-title":"Rheumatol Int"},{"key":"2021110402575348700_keab288-B35","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3899\/jrheum.181087","article-title":"Musculoskeletal ultrasound in systemic lupus erythematosus: systematic literature review by the Lupus Task Force of the OMERACT Ultrasound Working Group","volume":"46","author":"Wong","year":"2019","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab288\/38097057\/keab288.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5194\/41073243\/keab288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5194\/41073243\/keab288.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T03:00:33Z","timestamp":1635994833000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/11\/5194\/6207991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,4,1]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab288","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,4,1]]}}}